Nice job on the settlement, doc! I was also listening while working with the call on speakerphone in between seeing accounts. So I missed a lot unfortunately. Joe was really good in my opinion with Terry also sounding on point. I like the team as assembled. I heard at least two investors from here, TC and another who may not want his name known so I won’t say on his behalf. Both did a good job asking questions. I loved the vet, suffering long term effects from agent orange, thanks to him for his service! Joe did good in his response and understanding. I can emphasize with frustration from Joe because he gets accused of running a scheme when in reality he’s forgoing cash salary and using his pooled shares to make acquisitions that don’t dilute shareholders. So look at Olaregen as an example. Fda approval in 17 areas. Recent cash raised doesn’t go at all to back pay salaries to Joe, or future salaries, but to clinical work. Gnbt pays $400 grand, and utilitizes pooled shares. Does anyone think that’s a norm? That sounds Investor friendly to me.